The program, which includes OncoDNA, will evaluate the use of molecular diagnostic testing in personalizing treatments for cancer patients in Luxembourg.
The NCI will launch a lab network to provide researchers with centralized assays for conducting genomic and pharmacodynamic analysis for molecularly targeted drugs.
The analysis of HER2 and HER3 mutation carriers emphasizes how these studies can lead both to broadening and to narrowing of the patient populations for targeted drugs.
The changes include recommendations for first line immunotherapy in patients with high PD-L1 expression, and clarification on use of targeted therapies.
ASCO said MammaPrint should be used to inform decisions on withholding chemotherapy for these clinically high risk, HR-positive, HER2-negative breast cancers.
Some aspects of testing practice seem clear, while others present significant challenges for clinicians, according to discussions at the recent ASCO meeting.
